|
De novo metastatic versus recurrent gastroesophageal cancer: A single-centre retrospective analysis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis (Inst); Eisai; Ipsen; Ipsen; Novartis |
Research Funding - AstraZeneca (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst) |
|
|
Honoraria - AstraZeneca Canada; Bayer; Eisai; GlaxoSmithKline; Ipsen; Merck; Pfizer; Roche |
Research Funding - 1Globe Health Institute; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Mirati Therapeutics; Novartis; Nubiyota; Repare Therapeutics; Roche Canada |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Elekta (Inst); Novartis |
Research Funding - Bruce Power (Inst); Celgene/Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Adaptimmune (Inst); Astellas Pharma; BeiGene (Inst); Bristol-Myers Squibb (Inst); Viracta Therapeutics; Zymeworks (Inst) |
Research Funding - AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst) |